Alithea Genomics launches MERCURIUS FLASH-seq for enhanced single-cell RNA analysis
Swiss-American biotech company Alithea Genomics has unveiled MERCURIUS™ FLASH-seq, a revolutionary plate-based library preparation kit designed to transform full-length single-cell RNA sequencing capabilities for clinical and research laboratories.
Breakthrough sensitivity enables comprehensive gene detection
The newly launched system delivers exceptional gene capture rates, detecting up to two times more genes compared to existing commercially available solutions. Built upon methodology originally published in Nature Biotechnology, the enhanced FLASH-seq platform incorporates significant technical improvements that streamline laboratory workflows whilst maintaining superior data quality. “With MERCURIUS FLASH-seq, we are removing long-standing barriers in single cell RNA-seq to make full-length, high-resolution transcriptomics truly accessible,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “Researchers studying rare cells or running high-throughput screens no longer have to compromise between sensitivity, scale, and cost.”
Technical innovations address laboratory workflow challenges
The platform features a novel, non-toxic tagmentation buffer system that eliminates safety concerns whilst maintaining analytical performance. Available in both 96-and 384-well formats, the kit accommodates varying throughput requirements across different laboratory settings. MERCURIUS FLASH-seq provides comprehensive full-length transcript coverage, enabling researchers to examine differential gene expression patterns, detect alternative splicing events, and analyse isoform diversity – critical capabilities for understanding complex biological systems, particularly in rare cell populations.
Strategic positioning for drug discovery applications
The technology addresses fundamental challenges in translational research by offering high-resolution transcriptomic analysis without traditional compromises between sensitivity and scalability. This development supports accelerated drug discovery processes and enhanced disease biology characterisation. “This launch is a bold step toward accelerating drug discovery and deepening our understanding of disease biology,” added Dainese, highlighting the platform’s potential impact on pharmaceutical research pipelines.
Commercial availability and regulatory status
Alithea Genomics is currently accepting orders for MERCURIUS FLASH-seq kits and associated services.
For more information, visit: https://alitheagenomics.com/-flash-seq-news
Digital issue: Please click here for more information
